Temozolomide in the treatment of high-grade gliomas in children

A report from the Children's Oncology Group

Kenneth J Cohen, Ian F. Pollack, Tianni Zhou, Allen Buxton, Emiko J. Holmes, Peter C. Burger, Daniel J. Brat, Marc K. Rosenblum, Ronald L. Hamilton, Robert S. Lavey, Richard L. Heideman

Research output: Contribution to journalArticle

Abstract

To determine whether temozolomide is an active agent in the treatment of children with high-grade astrocytomas and whether survival is influenced by the expression of the O6-methylguanine-methyltransferase gene (MGMT) in these patients. In the Children's Oncology Group study ACNS0126, 107 patients with a diagnosis of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), or gliosarcoma were enrolled. All patients underwent concomitant chemoradiotherapy with temozolomide, followed by adjuvant chemotherapy with temozolomide. The outcomes were compared with those of children treated in Children's Cancer Group (CCG) study CCG-945. Formalin-fixed, paraffinembedded tumor tissue was available in 71 cases for immunohistochemical analysis of MGMT expression. Ninety patients were deemed eligible, 31 with AA, 55 with GBM, and 4 with other eligible diagnoses. The 3- year event-free survival (EFS) and overall survival (OS) rates were 11±3% and 22±5%, respectively. There was no evidence that temozolomide given during radiation therapy and as adjuvant therapy resulted in improved EFS compared with that found in CCG-945 (p 5 0.98). The 3-year EFS rate for AA was 13±6% in ACNS0126 compared with 22±5.5% in CCG-945 (p 5 0.95). The 3-year EFS rate for GBM was 7± 4% in ACNS0126 compared with 15±5% in CCG- 945 (p 5 0.77). The 2-year EFS rate was 17±5% among patients without MGMT overexpression and 5±4% among those with MGMT overexpression (p 5 0.045). Temozolomide failed to improve outcome in children with high-grade astrocytomas. MGMT overexpression was adversely associated with survival.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalNeuro-Oncology
Volume13
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

temozolomide
Glioma
Astrocytoma
Methyltransferases
Disease-Free Survival
Glioblastoma
Survival Rate
Neoplasms
Therapeutics
Genes
Gliosarcoma
Survival
Chemoradiotherapy
Adjuvant Chemotherapy

Keywords

  • High-grade glioma
  • Pediatric brain tumors
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., ... Heideman, R. L. (2011). Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group. Neuro-Oncology, 13(3), 317-323. https://doi.org/10.1093/neuonc/noq191

Temozolomide in the treatment of high-grade gliomas in children : A report from the Children's Oncology Group. / Cohen, Kenneth J; Pollack, Ian F.; Zhou, Tianni; Buxton, Allen; Holmes, Emiko J.; Burger, Peter C.; Brat, Daniel J.; Rosenblum, Marc K.; Hamilton, Ronald L.; Lavey, Robert S.; Heideman, Richard L.

In: Neuro-Oncology, Vol. 13, No. 3, 03.2011, p. 317-323.

Research output: Contribution to journalArticle

Cohen, KJ, Pollack, IF, Zhou, T, Buxton, A, Holmes, EJ, Burger, PC, Brat, DJ, Rosenblum, MK, Hamilton, RL, Lavey, RS & Heideman, RL 2011, 'Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group', Neuro-Oncology, vol. 13, no. 3, pp. 317-323. https://doi.org/10.1093/neuonc/noq191
Cohen, Kenneth J ; Pollack, Ian F. ; Zhou, Tianni ; Buxton, Allen ; Holmes, Emiko J. ; Burger, Peter C. ; Brat, Daniel J. ; Rosenblum, Marc K. ; Hamilton, Ronald L. ; Lavey, Robert S. ; Heideman, Richard L. / Temozolomide in the treatment of high-grade gliomas in children : A report from the Children's Oncology Group. In: Neuro-Oncology. 2011 ; Vol. 13, No. 3. pp. 317-323.
@article{d9cf6bef74f04388b0e68bb9c30e7750,
title = "Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group",
abstract = "To determine whether temozolomide is an active agent in the treatment of children with high-grade astrocytomas and whether survival is influenced by the expression of the O6-methylguanine-methyltransferase gene (MGMT) in these patients. In the Children's Oncology Group study ACNS0126, 107 patients with a diagnosis of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), or gliosarcoma were enrolled. All patients underwent concomitant chemoradiotherapy with temozolomide, followed by adjuvant chemotherapy with temozolomide. The outcomes were compared with those of children treated in Children's Cancer Group (CCG) study CCG-945. Formalin-fixed, paraffinembedded tumor tissue was available in 71 cases for immunohistochemical analysis of MGMT expression. Ninety patients were deemed eligible, 31 with AA, 55 with GBM, and 4 with other eligible diagnoses. The 3- year event-free survival (EFS) and overall survival (OS) rates were 11±3{\%} and 22±5{\%}, respectively. There was no evidence that temozolomide given during radiation therapy and as adjuvant therapy resulted in improved EFS compared with that found in CCG-945 (p 5 0.98). The 3-year EFS rate for AA was 13±6{\%} in ACNS0126 compared with 22±5.5{\%} in CCG-945 (p 5 0.95). The 3-year EFS rate for GBM was 7± 4{\%} in ACNS0126 compared with 15±5{\%} in CCG- 945 (p 5 0.77). The 2-year EFS rate was 17±5{\%} among patients without MGMT overexpression and 5±4{\%} among those with MGMT overexpression (p 5 0.045). Temozolomide failed to improve outcome in children with high-grade astrocytomas. MGMT overexpression was adversely associated with survival.",
keywords = "High-grade glioma, Pediatric brain tumors, Temozolomide",
author = "Cohen, {Kenneth J} and Pollack, {Ian F.} and Tianni Zhou and Allen Buxton and Holmes, {Emiko J.} and Burger, {Peter C.} and Brat, {Daniel J.} and Rosenblum, {Marc K.} and Hamilton, {Ronald L.} and Lavey, {Robert S.} and Heideman, {Richard L.}",
year = "2011",
month = "3",
doi = "10.1093/neuonc/noq191",
language = "English (US)",
volume = "13",
pages = "317--323",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Temozolomide in the treatment of high-grade gliomas in children

T2 - A report from the Children's Oncology Group

AU - Cohen, Kenneth J

AU - Pollack, Ian F.

AU - Zhou, Tianni

AU - Buxton, Allen

AU - Holmes, Emiko J.

AU - Burger, Peter C.

AU - Brat, Daniel J.

AU - Rosenblum, Marc K.

AU - Hamilton, Ronald L.

AU - Lavey, Robert S.

AU - Heideman, Richard L.

PY - 2011/3

Y1 - 2011/3

N2 - To determine whether temozolomide is an active agent in the treatment of children with high-grade astrocytomas and whether survival is influenced by the expression of the O6-methylguanine-methyltransferase gene (MGMT) in these patients. In the Children's Oncology Group study ACNS0126, 107 patients with a diagnosis of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), or gliosarcoma were enrolled. All patients underwent concomitant chemoradiotherapy with temozolomide, followed by adjuvant chemotherapy with temozolomide. The outcomes were compared with those of children treated in Children's Cancer Group (CCG) study CCG-945. Formalin-fixed, paraffinembedded tumor tissue was available in 71 cases for immunohistochemical analysis of MGMT expression. Ninety patients were deemed eligible, 31 with AA, 55 with GBM, and 4 with other eligible diagnoses. The 3- year event-free survival (EFS) and overall survival (OS) rates were 11±3% and 22±5%, respectively. There was no evidence that temozolomide given during radiation therapy and as adjuvant therapy resulted in improved EFS compared with that found in CCG-945 (p 5 0.98). The 3-year EFS rate for AA was 13±6% in ACNS0126 compared with 22±5.5% in CCG-945 (p 5 0.95). The 3-year EFS rate for GBM was 7± 4% in ACNS0126 compared with 15±5% in CCG- 945 (p 5 0.77). The 2-year EFS rate was 17±5% among patients without MGMT overexpression and 5±4% among those with MGMT overexpression (p 5 0.045). Temozolomide failed to improve outcome in children with high-grade astrocytomas. MGMT overexpression was adversely associated with survival.

AB - To determine whether temozolomide is an active agent in the treatment of children with high-grade astrocytomas and whether survival is influenced by the expression of the O6-methylguanine-methyltransferase gene (MGMT) in these patients. In the Children's Oncology Group study ACNS0126, 107 patients with a diagnosis of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), or gliosarcoma were enrolled. All patients underwent concomitant chemoradiotherapy with temozolomide, followed by adjuvant chemotherapy with temozolomide. The outcomes were compared with those of children treated in Children's Cancer Group (CCG) study CCG-945. Formalin-fixed, paraffinembedded tumor tissue was available in 71 cases for immunohistochemical analysis of MGMT expression. Ninety patients were deemed eligible, 31 with AA, 55 with GBM, and 4 with other eligible diagnoses. The 3- year event-free survival (EFS) and overall survival (OS) rates were 11±3% and 22±5%, respectively. There was no evidence that temozolomide given during radiation therapy and as adjuvant therapy resulted in improved EFS compared with that found in CCG-945 (p 5 0.98). The 3-year EFS rate for AA was 13±6% in ACNS0126 compared with 22±5.5% in CCG-945 (p 5 0.95). The 3-year EFS rate for GBM was 7± 4% in ACNS0126 compared with 15±5% in CCG- 945 (p 5 0.77). The 2-year EFS rate was 17±5% among patients without MGMT overexpression and 5±4% among those with MGMT overexpression (p 5 0.045). Temozolomide failed to improve outcome in children with high-grade astrocytomas. MGMT overexpression was adversely associated with survival.

KW - High-grade glioma

KW - Pediatric brain tumors

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=79955453343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955453343&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq191

DO - 10.1093/neuonc/noq191

M3 - Article

VL - 13

SP - 317

EP - 323

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -